Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery
Primary result · % time in target range 5.6-10.0 mmol/LResult — go to the resultMean difference 36.6 % 95% CI 18.5–54.8Authors' conclusion
Findings suggest that an adaptive SC FCL approach effectively accommodated the highly variable insulin needs in patients undergoing pancreatic surgery.
Study context
- Population
- Patients undergoing partial or total pancreatic resection
- Comparison
- Subcutaneous (SC) fully closed-loop vs usual care insulin therapy
- Primary endpoint
- % time with continuous glucose monitoring (CGM) values in target range 5.6–10.0 mmol/L
- Follow-up
- Over the time of hospitalization
Primary result
% time in target range 5.6-10.0 mmol/L
Mean difference
36.6 %
95% CI 18.5–54.8
By group
FCLvs UC
mean difference 36.6 % (95% CI 18.5–54.8)
As reported in the abstract
Safety
- Fully closed-loop (FCL) did not increase the risk of hypoglycaemia
Original publication
Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery. Diabetes Technol Ther. Published 14 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →